Pharmaceuticals & Therapeutics

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

Esperion's $75M+ deal for Corstasis and its novel nasal diuretic, Enbumyst, targets a $4B market and a new era of at-home edema management.

MAIA Biotechnology secured a crucial $30M to advance its promising lung cancer drug, but the move sent its stock plunging amid investor fears of dilution.

A federal policy loophole is diverting billions from struggling rural providers to wealthy urban hospitals, threatening care for millions of Americans.

A next-gen drug for chronic hives shows superior, faster results than the long-standing standard of care, heralding a potential shift in allergy treatment.

A new study aims to confirm a novel immunotherapy's dramatic results in colorectal cancer, offering hope for patients with limited treatment options.

Amorepacific's research-backed brand IOPE arrives at Sephora, challenging the US anti-aging market with patented technology and accessible pricing.

DRI Healthcare's strategic C$109M debt swap lowers interest costs, extends maturity, and signals strong investor confidence to fuel its acquisition pipeline.

A global coalition of advocates, doctors, and pharma giants launches Obesity Care Week, aiming to dismantle systemic barriers and fight pervasive weight bias.

With 175 million lenses implanted, Alcon solidifies its market leadership. Discover the technology giving patients unprecedented freedom from glasses.

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

In a strategic reverse merger with Rallybio, T-cell therapy innovator Candid Therapeutics secures over $505M to advance its groundbreaking autoimmune pipeline.

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

Hopes for a new Huntington's gene therapy face a major delay as the FDA rejects uniQure's current data and calls for a more rigorous, complex study.

A Chinese firm's 'Global Pioneer' status in cellular essence sparks debate on the future of biotech in cosmetics, medicine, and global regulation.

An 8-month-old infant weighing just 5.5 kg receives a new liver from his father in a daring surgery, marking a milestone for pediatric care in India.

Shareholder approval paves the way for cancer therapy innovator VERAXA to go public, aiming to accelerate its next-gen antibody-drug conjugate pipeline.

The FDA has greenlit Ascendis Pharma's once-weekly YUVIWEL for achondroplasia, a major step for patients that also carries significant business implications.

Facing delisting for being a 'public shell,' XTL Biopharma plans an appeal while its new acquisition and valuable IP hang in the balance.